文献速递肝病消化道肿瘤与早癌

循环胞外囊泡携带PD-1、PD-L1和CTLA-4提示肝细胞癌对抗PD-L1治疗耐药

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.
PubMed 文献 · Gut · 2026-08-06

结果显示EV-IC基线及早期动态可区分ICI治疗应答者与非应答者并预测PFS和OS,且能在影像学进展前约36-42周预测获得性耐药。

要点

  • EV上PD-1、PD-L1、CTLA-4在ICI治疗队列中可区分应答与非应答者。
  • EV-IC动态变化可预测PFS和OS,但在TKI治疗队列中不可重复。
  • EV-IC变化可在影像学进展前约36-42周提示获得性耐药。

核心结论

  • 携带PD-1、PD-L1和CTLA-4的胞外囊泡是可定量、非侵入性的生物标志物,用于预测晚期HCC患者ICI治疗的应答和生存,并比影像学更早识别免疫治疗耐药。

研究设计与样本

  • 分析了三个队列:HCC explorer队列(n=40)检测EV膜结合免疫检查点;早期HCC队列(n=37,配对血液和组织)评估EV与组织IC及临床病理参数的关系;治疗队列(n=202,600份序贯血样)含ICI治疗训练组(n=79,402份序贯样本)和验证组(n=82,146份序贯样本)及TKI治疗队列(n=41,52份序贯样本),通过多重免疫分析进行EV的IC谱分析。

主要发现

  • PD-1、PD-L1和CTLA-4在EV组分中较EV去除血清富集。
  • 在ICI治疗的训练和验证队列中,EV-IC的基线和早期动态显著区分应答者与非应答者,同时预测PFS和OS。
  • 这些发现在TKI治疗队列中不可重复。
  • 初始应答患者治疗期间EV-IC水平的动态变化预测获得性治疗耐药,约在影像学可追踪进展前36-42周。

临床怎么用

  • EV-IC谱分析可作为液体活检工具,用于晚期HCC患者ICI治疗的应答预测和生存分层。
  • 动态监测EV-IC水平有助于早期识别获得性耐药,可能早于影像学进展约36-42周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-line immune checkpoint inhibitor (ICI) therapy has contributed to improved outcomes in hepatocellular carcinoma (HCC). However, only around 30% of patients respond, highlighting the need for biomarker-driven patient selection. Considering the lack of tissue acquirement in HCC in clinical routine, liquid biopsy holds great promise. OBJECTIVE: We aimed at profiling immune checkpoints (IC) on circulating extracellular vesicles (EVs) as potential liquid biopsy-based biomarkers for prediction of treatment response. DESIGN: Three distinct cohorts were analysed in this study: (1) HCC explorer cohort (n=40), testing the presence of membrane-bound ICs on EVs; (2) early-stage HCC cohort (n=37 with paired blood and tissue), assessing the interplay between EV and tissue ICs alongside clinicopathological parameters and (3) treatment cohort (n=202 with 600 sequential blood samples), comprising an ICI treated cohort with a training (n=79, n=402 sequential samples) and a validation group (n=82, n=146 sequential samples), alongside a tyrosine-kinase inhibitor (TKI) treated cohort (n=41, n=52 sequential samples), to identify predictors of immunotherapy response through IC profiling of circulating EVs via multiplex immunoassay. RESULTS: Programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) were enriched in EV fractions compared to EV-depleted serum. Baseline and early dynamics of EV-IC levels significantly discriminated between responders and non-responders in the ICI-treated training and validation cohorts, while simultaneously predicting progression-free survival (PFS) and overall survival (OS). These findings were not reproducible in the TKI-treated cohort. In addition, dynamic changes of EV-IC levels during therapy in patients with initial response predicted acquired therapeutic resistance, approximately 36-42 weeks before progression was traceable on imaging. CONCLUSION: EVs carrying PD-1, PD-L1 and CTLA-4 represent readily quantifiable, non-invasive biomarkers to predict response and survival in patients with advanced HCC undergoing ICI therapy and serve to identify biological ICI resistance much earlier than current standards with imaging.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Gorgulho J, Masood R, Buescher G, et al. Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC. Gut. 2026. PMID: 42562419. doi:10.1136/gutjnl-2025-337617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。